{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:11:07Z","timestamp":1780920667069,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":116,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101231","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:52:14Z","timestamp":1777308734000},"page":"101231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prolonged sequential temozolomide in glioblastoma: A systematic review with exploratory quantitative synthesis"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0788-1205","authenticated-orcid":false,"given":"F.","family":"Pasqualetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bertolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pivato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Caccese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bellu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Acerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Soffietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Krengli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101231_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18222","article-title":"International patterns and trends in the brain cancer incidence and mortality: an observational study based on the global burden of disease","volume":"9","author":"Ilic","year":"2023","journal-title":"Heliyon."},{"key":"10.1016\/j.ctarc.2026.101231_bib0002","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of Glioblastoma Multiforme-Literature Review","volume":"14","author":"Grochans","year":"2022","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101231_bib0003","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-011-0749-4","article-title":"Glioblastoma survival in the United States before and during the temozolomide era","volume":"107","author":"Johnson","year":"2012","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101231_bib0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0006","article-title":"Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma","volume":"5","author":"Gupta","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.ctarc.2026.101231_bib0007","doi-asserted-by":"crossref","first-page":"748","DOI":"10.4236\/jct.2015.68082","article-title":"Protracted adjuvant temozolomide in Glioblastoma Multiforme","volume":"06","author":"Refae","year":"2015","journal-title":"JCT"},{"key":"10.1016\/j.ctarc.2026.101231_bib0008","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","article-title":"A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)","volume":"22","author":"Balana","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1357789","article-title":"Extended dosing (12 cycles) vs conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high-grade gliomas: a randomized, single-blind, two-arm, parallel-group controlled trial","volume":"14","author":"Anvari","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0009","doi-asserted-by":"crossref","first-page":"0","DOI":"10.21608\/zumj.2022.135444.2560","article-title":"Adjuvant Temozolamide six cycles versus extended twelve cycles In GLioblastoma multiform","volume":"0","author":"Elsebai","year":"2022","journal-title":"Zagazig Univ. Med. J."},{"key":"10.1016\/j.ctarc.2026.101231_bib0010","first-page":"XC04","article-title":"Comparative study of adjuvant temozolomide six cycles versus extended 12 cycles in newly diagnosed glioblastoma multiforme","volume":"11","author":"Bhandari","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.ctarc.2026.101231_bib0012","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2026.101231_bib0013","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem. Med. (Zagreb)"},{"key":"10.1016\/j.ctarc.2026.101231_bib0014","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0015","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","article-title":"A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without Vandetanib in newly diagnosed glioblastoma patients","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101231_bib0016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/neuonc\/noad119","article-title":"Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)","volume":"26","author":"Laprie","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0017","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/annonc\/mdu148","article-title":"Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF\u2020","volume":"25","author":"Chauffert","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0018","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101231_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.779491","article-title":"A systematic review and meta-analysis on the number of adjuvant temozolomide cycles in newly diagnosed glioblastoma","volume":"11","author":"Attarian","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104065","article-title":"The impact of survivorship bias in glioblastoma research","volume":"188","author":"Pasqualetti","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0022","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11060-022-04162-w","article-title":"Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis","volume":"160","author":"Wang","year":"2022","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ctarc.2026.101231_bib0023","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/WNL.0000000000003809","article-title":"Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma","volume":"88","author":"Gramatzki","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.ctarc.2026.101231_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104065","article-title":"The impact of survivorship bias in glioblastoma research","volume":"188","author":"Pasqualetti","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:45:30Z","timestamp":1780919130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"alternative-id":["S2468294226001425"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101231","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged sequential temozolomide in glioblastoma: A systematic review with exploratory quantitative synthesis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101231"}}